Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P240031/S004

Neuspera Sacral Neuromodulation (SNM) System

Neuspera Medical, Inc. · Decision date Apr 3, 2026

FDA DECISIONP240031/S004

What did the FDA decide?

FDA records P240031/S004 as a supplement to PMA P240031, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Apr 3, 2026.

FDA approval order statement

approval of an alternative supplier for the foreman needle component.
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Gastroenterology, Urology
Decision date
Apr 3, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record

Regulatory record facts

Identifier
P240031/S004
Regulatory pathway
PMA supplement
Product code
EZW
Decision code
OK30
Decision date
Apr 3, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Stimulator, electrical, implantable, for incontinence.

Product code
EZW
FDA device class
3

Review the original FDA PMA listing for the original approval scope and linked supplements.

FDA decision timeline

  1. P240031/S001 · Related supplement

    Neuspera Sacral Neuromodulation System

  2. P240031/S004 received

    Application receipt date recorded by FDA.

  3. P240031/S004 · FDA decision

    30-Day Notice

  4. P240031/S003 · Related supplement

    Neuspera Sacral Neuromodulation (SNM) System

  5. P240031/S005 · Related supplement

    Neuspera Sacral Neuromodulation (SNM) System

Timeline entries are records held by MedtechLedger for P240031. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P240031

Product / regulatory recordCompanyPathwayDecision dateSource
Neuspera Medical, Inc.PMA supplementAug 15, 2025FDA
Neuspera Medical, Inc.PMA supplementApr 21, 2026FDA
Neuspera Medical, Inc.PMA supplementAug 21, 2026FDA

Explore the linked device profile

Other records with product code EZW

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Neuspera Medical, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
51 Daggett Dr., San Jose, CA, 95134

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records